nach oben

Erschienen in:

24.07.2020 | main topic

COVID-19: frequently asked questions to the cardiologist

verfasst von: Andreas A. Kammerlander, MD, PhD, ao. Univ. Prof. Dr. Julia Mascherbauer

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 21-22/2020

Einloggen, um Zugang zu erhalten

Auszug

In December 2019, a previously unknown betacoronavirus was identified in a cluster of patients with pneumonia in Wuhan, China [1]. The pathogen was later named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), sharing similarities with already known SARS strains. The disease caused by SARS-CoV‑2 was named coronavirus disease 2019 (COVID-19) [2]. …

Vorheriger Artikel Analysis of Austrian COVID-19 deaths by age and sex

Nächster Artikel COVID-19 screening in outpatients with risk factors and healthcare workers

Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.CrossRef

Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. https://doi.org/10.1056/NEJMoa2002032CrossRef

Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A novel Coronavirus emerging in China—key questions for impact assessment. N Engl J Med. 2020;382(8):692–4.CrossRef

Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13.CrossRef

Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. Jama Cardiol. 2020; https://doi.org/10.1001/jamacardio.2020.0950.CrossRefPubMedPubMedCentral

Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with Coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020; https://doi.org/10.1001/jamacardio.2020.1017.CrossRefPubMedPubMedCentral

Guest TM, Ramanathan AV, Tuteur PG, Schechtman KB, Ladenson JH, Jaffe AS. Myocardial injury in critically ill patients. A frequently unrecognized complication. JAMA. 1995;273(24):1945–9.CrossRef

Fung G, Luo H, Qiu Y, Yang D, McManus B. Myocarditis. Circ Res. 2016;118(3):496–514.CrossRef

Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. 2020; https://doi.org/10.1093/eurheartj/ehaa190.CrossRefPubMedPubMedCentral

10.

Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel Coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS Coronavirus. J Virol. 2020; https://doi.org/10.1128/jvi.00127-20.CrossRefPubMedPubMedCentral

11.

Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. China CDC Weekly. 2020. http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51. Accessed 7 May 2020.

12.

Yang P, Gu H, Zhao Z, et al. Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury. Sci Rep. 2014;4:7027.CrossRef

13.

Mackey K, King VJ, Gurley S, et al. Risks and impact of Angiotensin-converting enzyme inhibitors or Angiotensin-receptor blockers on SARS-coV‑2 infection in adults. Ann Intern Med. 2020; https://doi.org/10.7326/m20-1515.CrossRefPubMedPubMedCentral

14.

Li J, Wang X, Chen J, Zhang H, Deng A. Association of Renin-Angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for Coronavirus disease 2019 (COVID-19) infection in Wuhan, China. Jama Cardiol. 2020; https://doi.org/10.1001/jamacardio.2020.1624.CrossRefPubMedPubMedCentral

15.

Zhang P, Zhu L, Cai J, et al. Association of inpatient use of Angiotensin converting enzyme inhibitors and Angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126(12):1671–1681. https://doi.org/10.1161/CIRCRESAHA.120.317134CrossRefPubMedPubMedCentral

16.

EMA, editor. EMA advises continued use of medicines for hypertension, heart or kidney disease during COVID-19 pandemic. 2020. https://www.ema.europa.eu/en/documents/press-release/ema-advises-continued-use-medicines-hypertension-heart-kidney-disease-during-covid-19-pandemic_en.pdf. Accessed 24 May 2020.

17.

HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19. https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19 (accessed on May 24, 2020).

18.

Considerations for Certain Concomitant Medications in Patients with COVID-19. NIH COVID-19 Treatment Guidelines (https://www.covid19treatmentguidelines.nih.gov/concomitant-medications/ accessed on May 24, 2020).

19.

Chieffo A, Stefanini GG, Price S, et al. EAPCI position statement on invasive management of acute coronary syndromes during the COVID-19 pandemic. Eur Heart J. 2020;41(19):1839–51.CrossRef

20.

Garcia S, Albaghdadi MS, Meraj PM, et al. Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic. J Am Coll Cardiol. 2020; https://doi.org/10.1016/j.jacc.2020.04.011.CrossRefPubMedPubMedCentral

21.

Antithrombotic Therapy in Patients with COVID-19. NIH COVID-19 Treatment Guidelines. (https://www.covid19treatmentguidelines.nih.gov/antithrombotic-therapy/ accessed on May 24, 2020).

22.

Klok FA, Kruip M, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020; https://doi.org/10.1016/j.thromres.2020.04.041.CrossRefPubMedPubMedCentral

23.

Barnes GD, Burnett A, Allen A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis. 2020; https://doi.org/10.1007/s11239-020-02138-z.CrossRefPubMedPubMedCentral

24.

ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance (accessed on May 25, 2020).

Titel: COVID-19: frequently asked questions to the cardiologist
verfasst von: Andreas A. Kammerlander, MD, PhD
ao. Univ. Prof. Dr. Julia Mascherbauer
Publikationsdatum: 24.07.2020
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 21-22/2020
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-020-01696-9

Impact of COVID-19 on Christmas

main topic

Fatal case of COVID-19 in a 27-year-old woman with diabetes mellitus

main topic

MUW researcher of the month

MUW researcher of the month

Analysis of Austrian COVID-19 deaths by age and sex

Open Access
main topic

COVID-19 screening in outpatients with risk factors and healthcare workers

main topic

SARS-CoV-2: recommendations for treatment in intensive care medicine

main topic

Springer Medizin Österreich

COVID-19: frequently asked questions to the cardiologist

Auszug

Weitere Artikel der Ausgabe 21-22/2020

Impact of COVID-19 on Christmas

Fatal case of COVID-19 in a 27-year-old woman with diabetes mellitus

MUW researcher of the month

Analysis of Austrian COVID-19 deaths by age and sex

COVID-19 screening in outpatients with risk factors and healthcare workers

SARS-CoV-2: recommendations for treatment in intensive care medicine

Springer Medizin Österreich

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Impact of COVID-19 on Christmas

Fatal case of COVID-19 in a 27-year-old woman with diabetes mellitus

MUW researcher of the month

Analysis of Austrian COVID-19 deaths by age and sex

COVID-19 screening in outpatients with risk factors and healthcare workers

SARS-CoV-2: recommendations for treatment in intensive care medicine